WO2011055968A3 - Nécessaire de détection d'une infection bactérienne comprenant des anticorps monoclonaux inédits - Google Patents

Nécessaire de détection d'une infection bactérienne comprenant des anticorps monoclonaux inédits Download PDF

Info

Publication number
WO2011055968A3
WO2011055968A3 PCT/KR2010/007710 KR2010007710W WO2011055968A3 WO 2011055968 A3 WO2011055968 A3 WO 2011055968A3 KR 2010007710 W KR2010007710 W KR 2010007710W WO 2011055968 A3 WO2011055968 A3 WO 2011055968A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptidoglycan
kit
bacterial infection
monoclonal antibodies
detecting bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/007710
Other languages
English (en)
Other versions
WO2011055968A2 (fr
Inventor
Jong-Gyun Kim
Sang-Koo Park
Byung-Hyun Choi
Jae-Sun Lee
Soo-Kwang Kim
Yoon-Seon Jang
Won-Jae Kwag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of WO2011055968A2 publication Critical patent/WO2011055968A2/fr
Publication of WO2011055968A3 publication Critical patent/WO2011055968A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un nécessaire de détection d'une infection bactérienne comprenant un anticorps monoclonal se liant de façon spécifique à une protéine de reconnaissance du peptidoglycane, ainsi qu'un anticorps monoclonal se liant de façon spécifique à un complexe de peptidoglycane et de protéine de reconnaissance du peptidoglycane. On peut détecter, au moyen de ce nécessaire, une infection bactérienne et ce, avec une grande spécificité et une grande affinité de liaison. Ces anticorps peuvent même, par exemple, détecter 20 pg de peptidoglycane de façon sélective. La présente invention concerne également des anticorps monoclonaux, c'est-à-dire un anticorps monoclonal se liant de façon spécifique à une protéine de reconnaissance du peptidoglycane et un anticorps monoclonal se liant, de façon spécifique, à un complexe de peptidoglycane et de protéine de reconnaissance du peptidoglycane, lesdits anticorps monoclonaux pouvant être utilisés dans un nécessaire de détection d'une infection bactérienne.
PCT/KR2010/007710 2009-11-05 2010-11-03 Nécessaire de détection d'une infection bactérienne comprenant des anticorps monoclonaux inédits Ceased WO2011055968A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090106308A KR101251023B1 (ko) 2009-11-05 2009-11-05 신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트
KR10-2009-0106308 2009-11-05

Publications (2)

Publication Number Publication Date
WO2011055968A2 WO2011055968A2 (fr) 2011-05-12
WO2011055968A3 true WO2011055968A3 (fr) 2011-09-29

Family

ID=43970533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007710 Ceased WO2011055968A2 (fr) 2009-11-05 2010-11-03 Nécessaire de détection d'une infection bactérienne comprenant des anticorps monoclonaux inédits

Country Status (2)

Country Link
KR (1) KR101251023B1 (fr)
WO (1) WO2011055968A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
SMT201700488T1 (it) 2012-02-15 2017-11-15 Novo Nordisk As Anticorpi che legano e bloccano il recettore d'innesco espresso sulle cellule mieloidi-1 (trem-1)
JP6400480B2 (ja) 2012-02-15 2018-10-03 ノヴォ ノルディスク アー／エス ペプチドグリカン認識タンパク質１に結合する抗体
EP3172232B1 (fr) 2014-07-17 2023-12-27 Novo Nordisk A/S Mutagenèse dirigée sur site d'anticorps trem-1 pour réduire la viscosité.
WO2016070001A1 (fr) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
EP3774902A1 (fr) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anticorps anti-trem-1 et utilisations associées
JP7660796B2 (ja) 2022-08-17 2025-04-14 ▲華▼中科技大学同▲済▼医学院附属▲協▼和医院 磁場調整可能なマイクロ磁気歯科矯正加速器
CN115825415B (zh) * 2022-09-28 2023-07-14 珠海重链生物科技有限公司 阻断剂和体外免疫诊断产品、应用
CN120718152B (zh) * 2025-09-01 2025-11-18 北京大学口腔医学院 一种特异性结合pglyrp1的单克隆抗体及其制备方法和应用
CN120737201B (zh) * 2025-09-01 2025-11-18 北京大学口腔医学院 一种靶向pglyrp1的单克隆抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090029973A (ko) * 2007-09-19 2009-03-24 주식회사유한양행 펩티도글리칸 인식 신호 전달에 관여하는 단백질, 이를코딩하는 유전자, 및 이를 포함하는 박테리아 감염 검출용키트
KR20090072078A (ko) * 2007-12-28 2009-07-02 주식회사유한양행 펩티도글리칸 인식 신호 전달에 관여하는 단백질, 이를코딩하는 유전자, 및 이를 포함하는 박테리아 감염 검출용키트

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090029973A (ko) * 2007-09-19 2009-03-24 주식회사유한양행 펩티도글리칸 인식 신호 전달에 관여하는 단백질, 이를코딩하는 유전자, 및 이를 포함하는 박테리아 감염 검출용키트
KR20090072078A (ko) * 2007-12-28 2009-07-02 주식회사유한양행 펩티도글리칸 인식 신호 전달에 관여하는 단백질, 이를코딩하는 유전자, 및 이를 포함하는 박테리아 감염 검출용키트

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIM, C.-H. ET AL.: "A three-step proteolytic cascade mediates the activation of the peptidoglycan-induced toll pathway in an insect.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 12, 21 March 2008 (2008-03-21), pages 7599 - 7607 *
PARK, J. ET AL.: "A synthetic peptidoglycan fragment as a competitive inhibitor of the melanization cascade.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 12, 24 March 2006 (2006-03-24), pages 7747 - 7755 *
PARK, J.-W. ET AL.: "Clustering of peptidoglycan recognition protein-SA is required for sensing lysine-type peptidoglycan in insects.", PROC. NATL. ACAD. SCI. USA, vol. 104, no. 16, 17 April 2007 (2007-04-17), pages 6602 - 6607 *
WANG, L. ET AL.: "Sensing of gram-positive bacteria in Drosophila: GNBP1 is needed to process and present peptidoglycan to PGRP-SA.", THE EMBO JOURNAL, vol. 25, no. 20, 5 October 2006 (2006-10-05), pages 5005 - 5014 *

Also Published As

Publication number Publication date
KR101251023B1 (ko) 2013-04-03
KR20110049334A (ko) 2011-05-12
WO2011055968A2 (fr) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2011055968A3 (fr) Nécessaire de détection d'une infection bactérienne comprenant des anticorps monoclonaux inédits
WO2008070229A3 (fr) Détection d'agrégats pathogènes de protéine dans un échantillon par elisa homologue
EP1700912A4 (fr) Methode de detection d'une molecule cible au moyen d'un aptamere
WO2011153300A3 (fr) Méthodes de détection d'anticorps monoclonaux pour des enzymes qui confèrent à des végétaux une résistance à l'acide 2,4-dichlorophénoxyacétique
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
JP2011512817A5 (fr)
WO2010065568A3 (fr) Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95
ZA201000093B (en) Detection of antigens carried by erythrocytes and of anti-erythrocyte antibodies
UA98983C2 (uk) Антитіло проти гепсидину та його застосування
MX346499B (es) Dispositivos, metodos y kits de inmunocromatografia.
WO2006124641A3 (fr) Anticorps diriges contre la mesotheline utiles pour des dosages immunologiques
EP1982993A3 (fr) Détection des infections principales avec des pathogènes
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
WO2009137677A3 (fr) Réactifs, procédés et systèmes de détection de staphylocoques résistants à la méthicilline (sarm)
WO2010009856A3 (fr) Protéine de liaison d’antigène goodpasture et sa détection
WO2006116631A3 (fr) Anticorps de l'isoforme de l'antigene nucleaire des cellules proliferatives cancereuses specifiques (pcnacs) et leurs utilisations
WO2011003598A3 (fr) Détection d'antigènes
WO2007067983A3 (fr) Anticorps specifique de la sulfotyrosine et utilisation a cet effet
WO2011113813A3 (fr) Dosage
WO2007144619A3 (fr) Anticorps innovants contre les protéines prions et leurs utilisations
WO2009016839A1 (fr) Procédé de mesure de la concentration d'un antigène
WO2011022438A3 (fr) Anticorps sensibles au clivage et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10828503

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10828503

Country of ref document: EP

Kind code of ref document: A2